A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a clinical trial published in The Lancet journal.

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of antiretrovirals to one-month refills since the U.S. government froze foreign ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

King Holmes, MD, PhD, an infectious diseases physician and researcher who helped create modern STI research and was a central ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Governments and global health groups are working to try to fill the most urgent gaps in the fight against diseases such as ...

Without public health surveillance, officials trying to tackle outbreaks, identify threats and evaluate treatments are ...

Millions of people worldwide are likely to lose access to anti HIV drugs, and thousands more people could die, after the US ...